TUMOR-TARGETED SUPERANTIGENS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 368

18. Forsberg G, Skartved NJ, Wallen-Ohman M, Nyhlen HC,
Behm K, Hedlund G, et al. (2010) Naptumomab estafenatox,
an engineered antibody-superantigen fusion protein with low
toxicity and reduced antigenicity. J. Immunother. 33, 492-499.
19. Erlandsson E, Andersson K, Cavallin A, Nilsson A, Larsson-
Lorek U, Niss U, et al. (2003) Identification of the antigenic
epitopes in staphylococcal enterotoxins A and E and design of
a superantigen for human cancer therapy. J. Mol. Biol. 333,
893-905.
20. Bjork P, Jonsson U, Svedberg H, Larsson K, Lind P, Dillner J,
et al. (1993) Isolation, partial characterization, and molecular
cloning of a human colon adenocarcinoma cell-surface glyco-
protein recognized by the C215 mouse monoclonal antibody.
J. Biol. Chem. 268, 24232-24241.
21. SundstedtA,CelanderM,HedlundG. (2008)Combining tumor-
targeted superantigens with interferon-alpha results in syner-
gistic anti-tumor effects. Int. Immunopharmacol. 8, 442-452.
22. Sundstedt A, Celander M, Ohman MW, Forsberg G, Hedlund
G. (2009) Immunotherapy with tumor-targeted superantigens
(TTS) in combination with docetaxel results in synergistic anti-
tumor effects. Int. Immunopharmacol. 9, 1063-1070.
23. Litton MJ, Dohlsten M, Hansson J, Rosendahl A, Ohlsson L,
Kalland T, et al. (1997) Tumor therapy with an antibody-
targeted superantigen generates a dichotomy between local and
systemic immune responses. Am. J. Pathol. 150, 1607-1618.
24. Forsberg G, Ohlsson L, Brodin T, Bjork P, Lando PA, Shaw D,
et al. (2001) Therapy of human non-small-cell lung carcinoma
using antibody targeting of a modified superantigen. Br. J.
Cancer 85, 129-136.
25. Lando PA, Dohlsten M, Ohlsson L, Kalland T. (1995) Tumor-
reactive superantigens suppress tumor growth in humanized
SCID mice. Int. J. Cancer 62, 466-471.
26. Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L,
Andersson J, et al. (1996) Antibody-targeted superantigen
therapy induces tumor-infiltrating lymphocytes, excessive
cytokine production, and apoptosis in human colon carcinoma.
Eur. J. Immunol. 26, 1-9.
27. Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M.
(1996) Immune response during tumor therapy with antibody-
superantigen fusion proteins. Int. J. Cancer 68, 109-113.
28. Rosendahl A, KristenssonK, CarlssonM, SkartvedNJ, Riesbeck
K, Sogaard M, et al. (1999) Long-term survival and complete
cures of B16 melanoma-carrying animals after therapy with
tumor-targeted IL-2 and SEA. Int. J. Cancer 81, 156-163.
29. Rosendahl A, Kristensson K, Hansson J, Ohlsson L, Kalland T,
Dohlsten M. (1998) Repeated treatment with antibody-targeted
superantigens strongly inhibits tumor growth. Int. J. Cancer
76, 274-283.
30. Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland
T, Dohlsten M. (1998) Perforin and IFN-gamma are involved
in the antitumor effects of antibody-targeted superantigens.
J. Immunol. 160, 5309-5313.
31. Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Sogaard M,
Andersson J, et al. (1999) The distinct role of CD4 þ and
CD8 þ T-cells during the anti-tumour effects of targeted super-
antigens. Br. J. Cancer 81, 359-366.

32. Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW,
Shannon B, et al. (1997) Superantigen-based immunotherapy: a
Phase I trial of PNU-214565, a monoclonal antibody-staphylo-
coccal enterotoxin A recombinant fusion protein, in advanced
pancreatic and colorectal cancer. J. Clin. Oncol. 15, 1994-2007.
33. Alpaugh RK, Schultz J, McAleer C, Giantonio BJ, Persson R,
Burnite M, et al. (1998) Superantigen-targeted therapy: Phase I
escalating repeat dose trial of the fusion protein PNU-214565
in patients with advanced gastrointestinal malignancies. Clin.
Cancer Res. 4, 1903-1914.
34. Lando PA, Dohlsten M, Hedlund G, Akerblom E, Kalland T.
(1993) T cell killing of human colon carcinomas by
monoclonal-antibody-targeted superantigens. Cancer Immu-
nol. Immunother. 36, 223-228.
35. Ouyang Q, Vilien M, Juhl BR, Larsen LG, Binder V. (1987)
CEA and carbohydrate antigens in normal and neoplastic colon
mucosa. An immunohistochemical study. Acta Pathol. Micro-
biol. Immunol. Scand. A 95, 177-183.
36. Haglund C, Lindgren J, Roberts PJ, Kuusela P, Nordling S.
(1989) Tissue expression of the tumour associated antigen
CA242 in benign and malignant pancreatic lesions. A
comparisonwith CA50 and CA19-9. Br. J. Cancer 60, 845-851.
37. Levy M, Visokai V, Lipska L, Topolcan O. (2008) Tumor
markers in staging and prognosis of colorectal carcinoma.
Neoplasma 55, 138-142.
38. ShawDM, ConnollyNB, Patel PM, Kilany S, HedlundG, Nordle
O, et al. (2007) A Phase II study of a 5T4 oncofoetal antigen
tumour-targeted superantigen (ABR-214936) therapy in patients
with advanced renal cell carcinoma. Br. J. Cancer 96, 567-574.
39. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C,
Rogatko A, et al. (2009) Phase I dose escalation, pharmaco-
kinetic and pharmacodynamic study of naptumomab estafe-
natox alone in patients with advanced cancer and with
docetaxel in patients with advanced non-small-cell lung can-
cer. J. Clin. Oncol. 27, 4116-4123.
40. Tordsson JM, Ohlsson LG, Abrahmsen LB, Karlstrom PJ,
Lando PA, Brodin TN. (2000) Phage-selected primate anti-
bodies fused to superantigens for immunotherapy of malignant
melanoma. Cancer Immunol. Immunother. 48, 691-702.
41. Tordsson J, Lavasani S, Ohlsson L, Karlstrom P, Svedberg H,
Abrahmsen L, et al. (2000) A3-a novel colon and pancreatic
cancer reactive antibody from a primate phage library selected
using intact tumour cells. Int. J. Cancer 87, 559-568.
42. Riesbeck K, Billstrom A, Tordsson J, Brodin T, Kristensson K,
Dohlsten M. (1998) Endothelial cells expressing an inflamma-
tory phenotype are lysed by superantigen-targeted cytotoxic
T cells. Clin. Diagn. Lab. Immunol. 5, 675-682.
43. Ragnarsson L, Stromberg T, Wijdenes J, Totterman TH,
Weigelt C. (2001) Multiple myeloma cells are killed by
syndecan-1-directed superantigen-activated T cells. Cancer
Immunol. Immunother. 50, 382-390.
44. Gidlof C, Carlson B, Dohlsten M, Totterman TH. (1998) Anti-
body-directed superantigen-mediated T-cell killing of myeloid
leukaemic cell line cells. Eur. J. Haematol. 60, 233-239.
45. Gidlof C, Dohlsten M, Lando P, Kalland T, Sundstrom C,
Totterman TH. (1997) A superantigen-antibody fusion protein